Genmab AS

Genmab AS Retained Earnings

The Retained Earnings of Genmab AS (GMAB) as of Nov 22, 2026 is 4.09 B USD. In the previous year, Retained Earnings was 23.55 B USD — a change of -82.64% (lower).

Retained Earnings

4.09 BUSD

YoY

-82.64%

Last updated:

Retained Earnings of Genmab AS is 2025 4.09 B USD. Retained Earnings of Genmab AS was 2024 23.55 B USD. It decreases by -82.64% lower compared to the previous year.

The Genmab AS Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2018
-197.46 M USD
Jan 1, 2019
2.13 B USD
Jan 1, 2020
7.11 B USD
Jan 1, 2021
10.02 B USD
Jan 1, 2022
14.81 B USD
Jan 1, 2023
19.02 B USD
Jan 1, 2024
23.55 B USD
Jan 1, 2025
4.09 B USD
The Genmab AS Retained Earnings history
YEARRetained EarningsYoY
4.09 BUSD-82.64%
23.55 BUSD+23.80%
19.02 BUSD+28.46%
14.81 BUSD+47.79%
10.02 BUSD+40.99%
7.11 BUSD+233.66%
2.13 BUSD-1,178.70%
-197.46 MUSD-89.35%
-1.85 BUSD-40.29%
-3.11 BUSD-26.54%
-4.23 BUSD-15.91%
-5.03 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

Retained Earnings of Genmab AS is 4.09 B USD in 2025.

Retained Earnings of Genmab AS changed from 23.55 B USD to 4.09 B USD, representing a -82.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings Genmab AS since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's Genmab AS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genmab AS

All Key Metrics — Genmab AS